Nanobiotix SA
PAR:NANO

Watchlist Manager
Nanobiotix SA Logo
Nanobiotix SA
PAR:NANO
Watchlist
Price: 3.01 EUR -6%
Market Cap: 141.9m EUR
Have any thoughts about
Nanobiotix SA?
Write Note

Nanobiotix SA
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nanobiotix SA
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Nanobiotix SA
PAR:NANO
Net Income (Common)
-€33.5m
CAGR 3-Years
8%
CAGR 5-Years
4%
CAGR 10-Years
-15%
Valneva SE
PAR:VLA
Net Income (Common)
€17.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Net Income (Common)
-€34.1m
CAGR 3-Years
-13%
CAGR 5-Years
N/A
CAGR 10-Years
-13%
G
Genfit SA
PAR:GNFT
Net Income (Common)
€22.3m
CAGR 3-Years
35%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Net Income (Common)
-€104.2m
CAGR 3-Years
-36%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Net Income (Common)
€6.6m
CAGR 3-Years
-57%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Nanobiotix SA
Glance View

Market Cap
141.8m EUR
Industry
Biotechnology

Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

NANO Intrinsic Value
4.3 EUR
Undervaluation 30%
Intrinsic Value
Price

See Also

What is Nanobiotix SA's Net Income (Common)?
Net Income (Common)
-33.5m EUR

Based on the financial report for Jun 30, 2024, Nanobiotix SA's Net Income (Common) amounts to -33.5m EUR.

What is Nanobiotix SA's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-15%

Over the last year, the Net Income (Common) growth was 43%. The average annual Net Income (Common) growth rates for Nanobiotix SA have been 8% over the past three years , 4% over the past five years , and -15% over the past ten years .

Back to Top